StockUS listing USLSBNASDAQHealthcareValue Trap

LakeShore Biopharma Co., Ltd(LSB) Stock Analysis | Healthcare

USD --+0.00%
Reward47Moderate
Risk54Moderate
75%Data
Thin -16% profit margin · Revenue growing 28% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 25.84M
Reward Ratingⓘ47 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ54 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LSB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is LakeShore Biopharma Co., Ltd?

, Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer.

AI Brief Pro

The brief on LakeShore Biopharma Co., Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is LakeShore Biopharma Co., Ltd?

, Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 25.84M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (47)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.57
Insider Activity
12M windowNo data
No insider activity data available for this ticker.